VLP Immunotherapy Composition for Targeted GBM Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Glioblastoma Multiforme (GBM) is challenging to treat due to its aggressive nature, resistance to chemotherapy, poor brain cell self-repair capacity, and lack of common tumor rejection antigens, leading to limited immunotherapeutic options and poor patient survival rates.
Innovation Solution
The use of virus-like particles (VLPs) expressing HCMV antigens gB and pp65, formulated with granulocyte macrophage colony stimulating factor (GM-CSF) as an adjuvant, administered intradermally in half-dose injections to stimulate immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used to treat GBM, then tumor cells are killed, but the tumor shows resistance and median survival is only three months
Solution Approach 1:
The patent introduces virus-like particles (VLPs) as intermediary carriers that display tumor-associated antigens on their surface. These VLPs serve as a bridge between the immune system and tumor cells, enabling targeted immune activation without direct cytotoxic chemotherapy. The VLPs mediate the interaction by presenting HCMV antigens (gB and pp65) that are specific to GBM cells, thereby triggering selective immune response against the tumor.
Solution Approach 2:
The patent replaces the mechanical/chemical cytotoxic mechanism of chemotherapy with an immunological mechanism. Instead of using chemical agents that non-selectively kill cells, the invention uses VLP-based immunotherapy to activate the immune system's biological defense mechanisms. The VLPs stimulate T cells and antibodies to recognize and destroy tumor cells through immune-mediated mechanisms, substituting the brute-force chemical attack with a targeted biological response.
2Reliability
If immunotherapy is used to target tumor antigens, then treatment specificity is improved, but autoimmunity risk increases
Solution Approach 1:
The patent applies local quality by using VLPs that display specific tumor-associated antigens (HCMV gB and pp65) on their surface. These antigens are locally expressed in the tumor microenvironment and are not uniformly present in healthy tissues. The VLPs present these specific antigens to the immune system, creating a localized immune response targeted at the tumor. This specificity is achieved because the VLPs only display antigens that are characteristic of GBM cells, thereby minimizing off-target effects and autoimmunity while maintaining high treatment specificity.
3Reliability
If VLPs expressing HCMV antigens are administered, then immune activation against GBM is enhanced, but the complexity of the therapeutic composition increases
Solution Approach 1:
The patent merges multiple functional elements into a single VLP structure. The VLPs combine the viral particle structure (for immune recognition and uptake) with tumor-associated antigen display (for specificity) and adjuvant components (for immune activation). By merging these elements into one integrated therapeutic unit, the patent simplifies the administration process while maintaining enhanced immune activation efficacy. The combined VLP formulation eliminates the need for separate administration of multiple agents, thereby reducing therapeutic complexity.
Data Source
AI summary
The present disclosure provides compositions and methods useful for treating Glioblastoma Multiforme (GBM), e.g., compositions comprising virus-like particles (VLPs) comprising Moloney Murine leukemia virus (MMLV) core proteins and the human cytomegalovirus epitopes, gB and pp65, formulated with GM-CSF, which, at dose of at least 10 μg gB/pp65Gag, reverse dysregulation of anti-HCMV immunity in GBM patients.